BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma

Blood

Volumn 125, Issue 4, 2015, Pages 658-667

  Correia, Cristina ^a   Schneider, Paula A ^a   Dai, Haiming ^a   Dogan, Ahmet ^a   Maurer, Matthew J ^a   Church, Amy K ^a   Novak, Anne J ^a   Feldman, Andrew L ^a   Wu, Xiaosheng ^b   Ding, Husheng ^a   Meng, X Wei ^a   Cerhan, James R ^a   Slager, Susan L ^a   Macon, William R ^a   Habermann, Thomas M ^a   Karp, Judith E ^c   Gore, Steven D ^c   Kay, Neil E ^a   Jelinek, Diane F ^a,b   Witzig, Thomas E ^a   Nowakowski, Grzegorz S ^a   Kaufmann, Scott H ^a   more..

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE DEAMINASE; PROTEIN BCL 2; IMMUNOGLOBULIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; GAIN OF FUNCTION MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CODE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOMATIC MUTATION; AGE; BIOSYNTHESIS; CELL TRANSFORMATION; CHROMOSOME 14; CHROMOSOME 18; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; RISK FACTOR; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; COHORT STUDIES; CYTIDINE DEAMINASE; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULINS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MUTATION; PREVALENCE; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK FACTORS; SURVIVAL RATE;

EID: 84921769871     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-571786     Document Type: Article

References (61)

1. Lunning MA, Vose JM. Management of indolent lymphoma: where are we now and where are we going. Blood Rev. 2012;26(6):279-288.
2. Sehn LH, Fenske TS, Laport GG. Follicular lymphoma: prognostic factors, conventional therapies, and hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(suppl 1): S82-S91.
3. Ujjani C, Cheson BD. The optimal management of follicular lymphoma: an evolving field. Drugs. 2013;73(13):1395-1403.
4. Hubbard SM, Chabner BA, DeVita VT Jr, et al. Histologic progression in non-Hodgkin's lymphoma. Blood. 1982;59(2):258-264.
5. Acker B, Hoppe RT, Colby TV, Cox RS, Kaplan HS, Rosenberg SA. Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol. 1983;1(1):11-16.
6. Garvin AJ, Simon RM, Osborne CK, Merrill J, Young RC, Berard CW. An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer. 1983;52(3):393-398.
7. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984;311(23):1471-1475.
8. Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15(4):1587-1594.
9. Giné E, Montoto S, Bosch F, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol. 2006;17(10):1539-1545.
10. Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25(17):2426-2433.
11. Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(32):5165-5169.
12. Nagy M, Balázs M, Adám Z, et al. Genetic instability is associated with histological transformation of follicle center lymphoma. Leukemia. 2000;14(12):2142-2148.
13. Li L, Gupta S, Bashir T, Koduru PR, Brody J, Allen SL. Serial cytogenetic alterations resulting in transformation of a low-grade follicular lymphoma to Burkitt lymphoma. Cancer Genet Cytogenet. 2006;170(2):140-146.
14. Maeshima AM, Omatsu M, Nomoto J, et al. Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma: morphological, immunohistochemical, and FISH analyses. Cancer Sci. 2008;99(9):1760-1768.
15. Schatz JH, Oricchio E, Puvvada SD, Wendel HG. Progress against follicular lymphoma. Curr Opin Hematol. 2013;20(4):320-326.
16. Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Reports. 2014;6(1):130-140.
17. Wong E, Dickinson M. Transformation in follicular lymphoma: biology, prognosis, and therapeutic options. Curr Oncol Rep. 2012;14(5):424-432.
18. Bernstein SH, Burack WR. The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology (Am Soc Hematol Educ Program). 2009;532-541.
19. Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol. 2011;29(14):1827-1834.
20. Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31(26):3272-3278.
21. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265.
22. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic factors in follicular lymphoma. J Clin Oncol. 2010;28(17):2902-2913.
23. Bello C, Zhang L, Naghashpour M. Follicular lymphoma: current management and future directions. Cancer Contr. 2012;19(3):187-195.
24. Nogai H, Dörken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol. 2011;29(14):1803-1811.
25. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest. 2012;122(10):3424-3431.
26. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335(6189):440-442.
27. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011;30(18):3667-3683.
28. Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci. 2009;122(pt 4):437-441.
29. Llambi F, Moldoveanu T, Tait SW, et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell. 2011;44(4):517-531.
30. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 1996;88(2):386-401.
31. Stavnezer J, Guikema JE, Schrader CE. Mechanism and regulation of class switch recombination. Annu Rev Immunol. 2008;26:261-292.
32. Lossos IS, Levy R, Alizadeh AA. AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity. Leukemia. 2004;18(11):1775-1779.
33. Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem. 2007;76:1-22.
34. Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet. 2008;40(1):108-112.
35. Halldórsdóttir AM, Frühwirth M, Deutsch A, et al. Quantifying the role of aberrant somatic hypermutation in transformation of follicular lymphoma. Leuk Res. 2008;32(7):1015-1021.
36. Bödör C, Bognár A, Reiniger L, et al. Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in mediastinal large B-cell lymphoma. Br J Haematol. 2005;129(3):373-376.
37. Pérez-Durán P, de Yebenes VG, Ramiro AR. Oncogenic events triggered by AID, the adverse effect of antibody diversification. Carcinogenesis. 2007;28(12):2427-2433.
38. Robbiani DF, Bothmer A, Callen E, et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell. 2008;135(6):1028-1038.
39. Seto M, Jaeger U, Hockett RD, et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J. 1988;7(1):123-131.
40. Tanaka S, Louie DC, Kant JA, Reed JC. Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas. Blood. 1992;79(1):229-237.
41. Reed JC, Tanaka S. Somatic point mutations in the translocated bcl-2 genes of non-Hodgkin's lymphomas and lymphocytic leukemias: implications for mechanisms of tumor progression. Leuk Lymphoma. 1993;10(3):157-163.
42. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature. 1991;349(6306):254-256.
43. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012;109(10):3879-3884.
44. Schuetz JM, Johnson NA, Morin RD, et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia. 2012;26(6):1383-1390.
45. Okosun J, Bödör C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46(2):176-181.
46. Dai H, Meng XW, Lee S-H, Schneider PA, Kaufmann SH. Context-dependent Bcl-2/Bak interactions regulate lymphoid cell apoptosis. J Biol Chem. 2009;284(27):18311-18322.
47. Smith AJ, Dai H, Correia C, et al. Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem. 2011;286(20):17682-17692.
48. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
49. Cheson BD, Pfistner B, Juweid ME, et al International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
50. Weber JS, Berry J, Litwin S, Claflin JL. Somatic hypermutation of the JC intron is markedly reduced in unrearranged kappa and H alleles and is unevenly distributed in rearranged alleles. J Immunol. 1991;146(9):3218-3226.
51. Deng X, Gao F, Flagg T, May WS Jr. Mono- and multisite phosphorylation enhances Bcl2's antiapoptotic function and inhibition of cell cycle entry functions. Proc Natl Acad Sci USA. 2004;101(1):153-158.
52. Jin Z, May WS, Gao F, Flagg T, Deng X. Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. J Biol Chem. 2006;281(20):14446-14456.
53. Dai H, Ding H, Meng XW, Lee S-H, Schneider PA, Kaufmann SH. Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. Cancer Res. 2013;73(23):6998-7008.
54. Matolcsy A, Casali P, Warnke RA, Knowles DM. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood. 1996;88(10):3937-3944.
55. Green MR, Gentles AJ, Nair RV, et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 2013;121(9):1604-1611.
56. Guidugli L, Carreira A, Caputo SM, et al; ENIGMA consortium. Functional assays for analysis of variants of uncertain significance in BRCA2. Hum Mutat. 2014;35(2):151-164.
57. Duquette ML, Huber MD, Maizels N. G-rich protooncogenes are targeted for genomic instability in B-cell lymphomas. Cancer Res. 2007;67(6):2586-2594.
58. Freedman A. Follicular lymphoma: 2012 update on diagnosis and management. Am J Hematol. 2012;87(10):988-995.
59. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell. 1999;3(3):287-296.
60. Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 2003;8(4):345-352.
61. Dai H, Pang Y-P, Ramirez-Alvarado M, Kaufmann SH. Evaluation of the BH3-only protein Puma as a direct Bak activator. J Biol Chem. 2014;289(1):89-99.